Salspera Presents Data on Saltikva (Salmonella-IL2) in Metastatic Pancreatic Cancer at the European Association for Cancer Research 2021 Virtual Conference Defence is the Best Attack: Immuno-Oncology Breakthroughs

OAKDALE, Feb. 18th, 2021 - Salspera, LLC, a clinical-stage biopharmaceutical company dedicated to the development of microbial based immunotherapies for cancer, yesterday presented an overview of the ongoing Phase II clinical study of Saltikva (Salmonella-IL2) in metastatic pancreatic cancer (NCT04589234) at the European Association for Cancer Research 2021 conference Defence is the Best Attack: Immuno-Oncology Breakthroughs.

Title: A Phase 2 Study of Saltikva (Salmonella-IL2) in Metastatic Pancreatic Cancer

Presenters: Daniel Saltzman, MD PhD; Eddie Moradian, PhD

View Poster

About Salspera

Salspera is a private, clinical stage biotech company developing its platform of orally administered microbiome immunotherapies in solid tumors. The deep pipeline consists of orally administered microbiome immunotherapies, genetically engineered to eliminate pathogenicity and express various cytokines and cytotoxic proteins within the tumor microenvironment. The lead asset, Saltikva, is currently in an on-going phase 2 clinical study in Stage 4 metastatic pancreatic cancer patients in Canada. It is also being developed in additional solid tumors with the plan to initiate further phase 2 studies. The platform consists of numerous constructs engineered to deliver among others, PD-L1, CTLA-4, IL-15 intra-tumorally. These are currently undergoing IND enabling studies with plans to move them to the clinic.

For more information, please visit salspera.com.

Salspera Contact

Chandler Glass

VP of Business Development

cglass@salspera.com